SCHEMBL12247255

SCHEMBL12247255

CC1(C)c2ccccc2-c2cc3c(-c4ccc(-c5ccccn5)cn4)c4ccccc4c(-c4ccc5ccccc5c4)c3cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
TSHR P16473 1/20 0.35
KLF5 Q13887 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ABL1 P00519 2/20 0.35
HTR2C P28335 1/20 0.32
DHODH Q02127 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
WNT3A P56704 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13459681 0.95 KDM4E (0.36) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247263 0.95 KDM4E (0.36) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247010 0.90 KDM4E (0.37) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247332 0.89 KDM4E (0.36) KDM4EALDH1A1LMNATP53MAPT
SCHEMBL12247282 0.88 PDK2 (0.40) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247260 0.88 PDK2 (0.40) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247298 0.88 PDK2 (0.39) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247321 0.87 KDM4E (0.35) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL13488050 0.87 PDK2 (0.40) PDK2KDM4EALDH1A1LMNATP53
SCHEMBL12247027 0.87 PDK2 (0.40) PDK2KDM4EALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-8525158-B2 Anthracene derivative and organic electroluminescence element using the same DOOSAN CORPORATION (KR) 2013-09-03 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME DOOSAN CORPORATION (KR) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110210320-A1 ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME KCNJ2, KCNJ1, BRD4 PDK2 646/4885KDM4E 913/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.